Study guide
7.2 Surgical Oncology, Perioperative Care & Reconstruction
Advanced Oncology Certified Nurse Practitioner AOCNP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide
2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening
2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling
3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging
3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment
4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship
4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence
5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy
5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring
6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies
6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology
7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy
7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies
8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response
8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)
9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety
9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions
10 Chapter 10: Supportive Care - Symptom & Comorbidity Management
10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management
11 Chapter 11: Oncologic Emergencies
11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH
12 Chapter 12: Psychosocial Issues
12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources
13 Chapter 13: Professional Practice & Roles of the APRN
13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education
7.2 Surgical Oncology, Perioperative Care & Reconstruction
Key Takeaways Explain This Topic AI
Surgical oncology serves diagnostic, staging, curative, cytoreductive (debulking), palliative, and risk-reducing (prophylactic) roles in solid tumor management.
Surgical margin status is categorized pathologically as R0 (no residual microscopic tumor), R1 (microscopic residual tumor at margin), and R2 (macroscopic gross residual tumor).
Neoadjuvant therapy aims to downstage tumors prior to resection, requiring strict timing intervals before surgery to avoid wound healing complications, especially holding anti-VEGF agents like bevacizumab for at least 4 to 6 weeks pre- and postoperatively.
Sentinel lymph node biopsy (SLNB) accurately identifies regional lymph node metastasis while avoiding the morbidity of complete lymph node dissection (CLND) in node-negative breast cancer and melanoma.
Enhanced Recovery After Surgery (ERAS) protocols and aggressive APRN perioperative management reduce postoperative complications, including surgical site infections, wound dehiscence, anastomotic leaks, and venous thromboembolism.
Last updated: August 2026
Surgical Oncology, Perioperative Care & Reconstruction
Surgical oncology remains the oldest and most definitive curative modality for the majority of solid tumors. Beyond primary curative resection, surgical interventions are integral across the entire cancer care continuum—from initial tissue diagnosis and staging to palliation of oncologic emergencies and complex reconstruction. For the Advanced Practice Registered Nurse (APRN), effective surgical oncology management requires synthesizing surgical principles, pathologic staging, multimodal sequencing timing, perioperative optimization, and postoperative complication surveillance.
1. Surgical Roles Across the Cancer Continuum
Oncologic surgical procedures are broadly categorized by their primary clinical intent:
Surgical Intent Clinical Objective Clinical Example
Diagnostic Obtain representative tissue for pathologic, histologic, and biomarker grading. Core needle biopsy, incisional/excisional biopsy.
Staging Determine anatomical extent of disease to guide definitive treatment planning. Sentinel lymph node biopsy (SLNB), staging laparoscopy with peritoneal washings.
Curative (Primary) Resect primary tumor completely with adequate negative margins and regional nodes. Radical mastectomy, lobectomy, low anterior resection, radical nephrectomy.
Cytoreductive (Debulking) Reduce total tumor burden when complete resection is impossible, enhancing systemic therapy efficacy. Cytoreductive surgery + Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in advanced ovarian cancer.
Palliative Relieve symptoms, prevent impending oncologic emergencies, and improve quality of life. Surgical bypass for malignant bowel obstruction, spinal cord decompression, palliative orthopedic fixation.
Risk-Reducing (Prophylactic) Remove high-risk target organs prior to malignant transformation in hereditary cancer syndromes. Bilateral risk-reducing mastectomy and salpingo-oophorectomy (RRSO) in BRCA1/2 mutation carriers.
- 2. Pathologic Margins & Nodal Staging Principles
- Pathologic Surgical Margins
The primary goal of curative surgical oncology is achieving en bloc resection of the primary tumor with clear, micro- and macroscopically negative anatomical margins.
R0 Resection : Complete tumor resection with negative microscopic margins (no cancer cells at the inked surgical edge). Represents the prerequisite for surgical cure.
R1 Resection : Microscopic residual tumor identified at the resected margin by the pathologist. Associated with high rates of local recurrence; requires consideration of re-excision or adjuvant radiation/systemic therapy.
R2 Resection : Macroscopic (gross) residual tumor left behind postoperatively. Indicates incomplete resection; converts surgical intent to debulking or palliation.
Tumor-Specific Margin Guidelines
Cutaneous Melanoma : Margin size dictated strictly by Breslow thickness:
Melanoma in situ : 0.5 cm margin.
Breslow < 1.0 mm < 1.0\text{ mm} < 1.0 mm : 1.0 cm margin.
Breslow 1.01 – 2.0 mm 1.01–2.0\text{ mm} 1.01–2.0 mm : 1.0 to 2.0 cm margin.
Breslow > 2.0 mm > 2.0\text{ mm} > 2.0 mm : 2.0 cm margin.
Breast Conservation Therapy (Lumpectomy) :
Invasive Breast Cancer : "No ink on tumor" (no tumor cells directly touching the inked margin).
Ductal Carcinoma in Situ (DCIS) : Minimum 2.0 mm clear margin.
Colon Cancer : Minimum 5.0 cm clear proximal and distal bowel margins along with en bloc resection of the draining mesentery containing at least 12 regional lymph nodes.
Sentinel Lymph Node Biopsy (SLNB) vs. Complete Dissection
SLNB Rationale : The sentinel lymph node is the first node(s) receiving lymphatic drainage from a primary tumor. Injecting radiocolloid (Technetium-99m) and/or isosulfan blue dye identifies sentinel nodes. If the sentinel node is pathologically negative, the remainder of the nodal basin is negative with > 95 % >95\% > 95% certainty.
Clinical Benefit : Omitting Complete Lymph Node Dissection (CLND) in sentinel-negative patients drastically reduces upper/lower extremity chronic lymphedema, wound seromas, sensory paresthesias, and chronic pain while maintaining equivalent overall survival in breast cancer and melanoma.
3. Multimodal Integration & Perioperative Timing
Modern solid tumor management relies on integrating surgery with neoadjuvant (preoperative) and adjuvant (postoperative) systemic therapy and radiation. Neoadjuvant Therapy (Systemic / RT)
- ├── Purpose: Tumor downstaging, early micrometastatic control, organ preservation
- └── Surgical Hold Window: Allow bone marrow & tissue recovery (typically 4-6 weeks)
- │
- ▼
- Definitive Surgical Resection (R0 Goal)
- └── Wound Healing & Recovery Window: 4 to 6 weeks
- │
- ▼
- Adjuvant Therapy (Chemotherapy / RT / Endocrine)
- └── Purpose: Eradicate microscopic residual disease
- Critical Anti-VEGF & Targeted Drug Hold Times
Administering targeted anti-angiogenic agents or cytotoxic chemotherapy too close to surgical procedures compromises physiological wound healing and increases catastrophic perioperative morbidity:
Bevacizumab (Anti-VEGF Monoclonal Antibody) : Inhibits endothelial repair and collagen synthesis. Must be held for at least 4 to 6 weeks prior to elective surgery and held for at least 4 to 6 weeks postoperatively until all surgical incisions are completely healed. Premature surgery increases risks of wound dehiscence, fatal surgical hemorrhage, and bowel perforation.
Tyrosine Kinase Inhibitors (TKIs) : VEGFR-TKI agents (e.g., sunitinib, pazopanib) should be held 3 to 7 days pre- and postoperatively.
Cytotoxic Chemotherapy : Usually held 3 to 4 weeks prior to surgery to allow complete hematologic recovery (absolute neutrophil count > 1.5 × 10 9 / L >1.5 \times 10^9/\text{L} > 1.5 × 1 0 9 / L , platelets > 100 × 10 9 / L >100 \times 10^9/\text{L} > 100 × 1 0 9 / L ). Postoperative adjuvant chemotherapy should ideally initiate within 4 to 8 weeks after surgery once healing is verified.
- 4. APRN Perioperative Management & ERAS Protocols
- Enhanced Recovery After Surgery (ERAS)
ERAS protocols represent evidence-based multimodal perioperative pathways designed to attenuate the surgical stress response, maintain physiological homeostasis, and accelerate recovery:
Preoperative : Avoid prolonged fasting (allow clear fluids up to 2 hours pre-op), carbohydrate loading drinks, selective bowel preparation, preoperative nutritional optimization.
Intraoperative : Goal-directed fluid therapy (avoid fluid overload), short-acting anesthetic agents, normothermia maintenance, opioid-sparing multimodal analgesia (regional blocks, acetaminophen, NSAIDs/celecoxib, gabapentinoids).
Postoperative : Early removal of urinary catheters and surgical drains, early oral refeeding, early ambulation within 24 hours post-op, aggressive VTE prophylaxis.
Postoperative Complication Surveillance
Surgical Site Infection (SSI) : Erythema, purulent drainage, localized warmth, fever > 38.0 ∘ C >38.0^\circ\text{C} > 38. 0 ∘ C . Obtain wound cultures and initiate targeted antibiotic therapy.
Wound Dehiscence & Evisceration : Separation of surgical wound layers. Risk factors include obesity, malnutrition, corticosteroids, prior radiation, and bevacizumab. Evisceration requires immediate application of sterile saline-soaked dressings and emergency surgical exploration.
Anastomotic Leak : Occurs following gastrointestinal resections (typically post-op days 4–7). Clinical signs include persistent tachycardia, fever, severe abdominal pain, peritonitis, purulent/fecal drain output, and acute sepsis. Emergency CT scan with oral/IV contrast is diagnostic.
Venous Thromboembolism (VTE) : High risk in oncology surgical patients. Prophylaxis requires mechanical compression devices combined with low-molecular-weight heparin (LMWH, e.g., enoxaparin 40 mg SC daily) continued for 28 days postoperatively for high-risk abdominal/pelvic cancer resections.
5. Reconstruction & Oncologic Rehabilitation
Reconstructive surgical oncology restores form and function following extensive tissue extirpation:
Breast Reconstruction : Autologous tissue transfer flaps (Deep Inferior Epigastric Perforator [DIEP] flap, Transverse Rectus Abdominis Myocutaneous [TRAM] flap, Latissimus Dorsi flap) vs. prosthetic implant-based reconstruction (tissue expanders followed by permanent implants).
Lymphedema Prevention & Surgical Management : In patients with severe secondary lymphedema refractory to conservative compression therapy, microsurgical techniques such as Lymphaticovenous Anastomosis (LVA) (bypassing obstructed lymphatics into subdermal veins) or Vascularized Lymph Node Transfer (VLNT) can significantly improve fluid drainage.